C. difficile 위험도


UTIModerate or severe infectionLife-threatening infection0.5-1 g IV q8-12h1-2 g IV q8-12h2 g IV 6-8h (max 8 g/d)

Mild or moderate infectionSevere infectionSafety and efficacy in pediatric patients <9m of age have not been established30 mg/kg IV q8h30 mg/kg IV q6-8h (max 120 mg/kg/d)

No dose adjustment

CrCl >30CrCl 10-30CrCl <10HD & life-threatening infectionNo dose adjustment50% recommended dose at recommended intervals25% recommended dose at recommended intervalsAdditional 125% recommended dose IV after HD

General Information

Therapy of gram-negative infections including Pseudomonas, particularly in patients with penicillin and cephalosporin allergy or when there is no alternative susceptible agent.

Nebulized form used in cystic fibrosis patients.

Empiric therapy for febrile neutropenia.

Monitor liver enzymes, renal and hepatic functions.


  • Chest discomfort

  • Abdominal pain

  • Vomiting

  • Elevated liver enzymes

  • Serum creatinine raised

  • Cough

  • Nasal congestion

  • Throat pain

  • Wheezing

  • Fever


  • Erythema multiforme

  • Toxic epidermal necrolysis

  • Clostridium difficile colitis, diarrhea

  • Gastrointestinal hemorrhage

  • Neutropenia

  • Pancytopenia

  • Thrombocytopenia

  • Hepatitis

  • Jaundice

  • Ototoxicity

  • Nephrotoxicity

  • Angioedema

  • Anaphylaxis

Cholera vaccine, live

Antimicrobial class: Monobactam

Pregnancy category: B

Average serum half life: 2 hours

Biliary penetration: Moderate

Lung penetration: Therapeutic

Urine penetration: Therapeutic


  • Discontinue if allergic reaction or chest tightness occurs.

  • Pulmonary exacerbation may occur with reduction in FEV1 following completion of 28-day course.

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.